Featured Image: Laboratory Glass works. Courtesy: © 2010 - 2018. Fotolia Used with permission.

A new article, published by a team of writers including Muhammad Kalim, Jie Chen, and Shenghao Wang from the Department of Biochemistry and Genetics, School of Medicine, College of Pharmaceutical Science, Zhejiang University, Hangzhou, People’s Republic of China, discusses the Intracellular Trafficking of New Anticancer Therapeutics.[1]

Antibody–drug conjugates or ADCs are a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes place via clathrin-mediated endocytosis, caveolae-mediated endocytosis, and pinocytosis.

Conjugation strategies, endocytosis and intracellular trafficking optimization, linkers, and drugs chemistry present a great challenge for researchers to eradicate tumor cells successfully.

This inventiveness of endocytosis and intracellular trafficking has given consi­derable momentum recently to develop specific antibodies and ADCs to treat cancer cells. It is significantly advantageous to emphasize the endocytosis and intracellular trafficking pathways efficiently and to design potent engineered conjugates and biological entities to boost efficient therapies enormously for cancer treatment.

Advertisement #3

Current studies illustrate endocytosis and intracellular trafficking of ADC, protein, and linker strategies in unloading and also concisely evaluate practically applicable antibody-drug conjugates.

This article was supported by the National Nature Science Foundation of China and Special Program from the Department of Science and Technology, Zhejiang Province, People’s Republic of China.

Last editorial review: August 1, 2017

Featured Image: est tubes in clinic, pharmacy and medical research laboratory with male scientist using pipette Courtesy: © 2017. Fotolia. Used with permission.

Copyright © 2017 InPress Media Group, LLC. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.